Results 31 to 40 of about 82,508 (316)

Development of Bone Targeting Drugs. [PDF]

, 2017
The skeletal system, comprising bones, ligaments, cartilage and their connective tissues, is critical for the structure and support of the body. Diseases that affect the skeletal system can be difficult to treat, mainly because of the avascular cartilage
Alméciga-Díaz, Carlos J., Mackenzie, William G., Mason, Robert W., Orii, Tadao, Sawamoto, Kazuki, Stapleton, Molly, Tomatsu, Shunji   +6 more
core   +2 more sources

BISPHOSPHONATE INDUCED OSTEONECROSIS OF THE JAWS AND CURRENT THERAPIES

Cumhuriyet Dental Journal, 2017
Bisphosphonates are pharmacological agents which are the potent inhibitors of osteoclastic activity. Nowadays, bisphosphonates are used to treat a variety of bone disease or related complications such as metastatic or osteolytic bone disease ...
Damla Torul, Mehmet Cihan Bereket
doaj   +1 more source

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis [PDF]

, 2006
BACKGROUND: Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. METHODS: We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration ...
Ale Algra, Anne-Margriet Huisman, Ans C.M. Oostveen, Ben A.C. Dijkmans, Chris E.D. de Laet, de Nijs RN, Erik Buskens, George A.W. Bruyn, Johannes W.G. Jacobs, Johannes W.J. Bijlsma, Michel BA, Piet P.M.M. Geusens, Roland F.J. Laan, Ron N.J. de Nijs, Willem F. Lems   +14 more
core   +4 more sources

ATYPICAL FRACTURES DUE TO LONG TREATMENT WITH BISPHOSPHONATES (CRITICAL REVIEW)

Travmatologiâ i Ortopediâ Rossii, 2013
This paper reviews the evidence for an association between atypical subtrochanteric fractures and long-term bisphosphonate use. A PubMed search of literature was performed.
G. S. Golubev
doaj   +1 more source

Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial [PDF]

, 2018
Background Tiludronate and clodronate are FDA-approved bisphosphonate drug therapies for navicular disease in horses. Although clinical studies have determined their ability to reduce lameness associated with skeletal disorders in horses, data regarding
Gillett, Ashley N., McNulty, Margaret A., Mitchell, Colin F., Richbourg, Heather A.   +3 more
core   +1 more source

Therapeutic potential of bisphosphonates - review of medical indications, mechanism of action, interactions and adverse effects

Journal of Education, Health and Sport
Introduction: Bisphosphonates are pharmacological agents that inhibit bone resorption by targeting osteoclasts, thereby increasing bone density and reducing fracture risk.
Agnieszka Mikosińska, Mateusz Litwin, Jakub Parys, Patrycja Kałuziak, Aleksandra Witek, Martyna Kaźmierczak, Stanisław Jesionek, Marta Jajczak, Maciej Mossakowski   +8 more
doaj   +1 more source

Bisphosphonates and osteonecrosis of jaws

Journal of Indian Academy of Oral Medicine and Radiology, 2012
Bisphosphonates are used to treat osteoporosis. Paget disease of bone and other metabolic bone diseases, multiple myeloma, and skeletal events associated with metastatic neoplasms- In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in ...
Geetha Vijay, Vijay Raghavan
doaj   +1 more source

Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study [PDF]

, 2018
Introduction: The management of bisphosphonate-related osteonecrosis of the jaw (BRONJ), with no evidence-based guidelines, remains controversial. We aimed to evaluate the efficiency of a conservative surgical treatment combining Er,Cr:YSGG laser and ...
Albanese, Antonino, Bedogni, Alberto, Campisi, Giuseppina, Cumbo, Enzo Maria Giuseppe, Di Fede, Olga, Licata, Maria Ester, Maniscalco, Laura, Mauceri, Rodolfo, Mazzola, Giuseppina, Panzarella, Vera, Toia, Francesca   +10 more
core   +1 more source

Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication

Saudi Pharmaceutical Journal, 2018
Introduction: In October 2010, the US Food and Drug Administration (FDA) issued a safety communication regarding the risks of atypical fractures of the femur, with bisphosphonates drugs.
Bander Balkhi, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio   +2 more
doaj   +1 more source

Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. [PDF]

, 2011
The relaxed complex scheme, a virtual-screening methodology that accounts for protein receptor flexibility, was used to identify a low-micromolar, non-bisphosphonate inhibitor of farnesyl diphosphate synthase.
Cao, Rong, Durrant, Jacob D, Gorfe, Alemayehu A, Li, Jikun, McCammon, J Andrew, Oldfield, Eric, Sankovsky, Anna, Zhu, Wei   +7 more
core   +2 more sources